Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

Palbociclib (brand name Ibrance) was the first CDK 4/6 inhibitor approved by the FDA to treat breast cancer. In combination, ...

Unlocking the potential of next-generation breast cancer treatments “The emergence of CDK inhibitors for the treatment of breast cancer has been pivotal in improving the standard of care for ...

Recent work has discovered the role of the cyclin-dependent kinase (CDK)-binding protein Cks1 in ... replication and is aberrantly enhanced in cancer. Surprisingly, new work indicates that this ...

Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation, development, and cancer biology. An additional major ...

My laboratory has combined biochemical, molecular, cellular, and genetic approaches to investigate the roles of CDK inhibitors in differentiation, development, and cancer biology. An additional major ...

CDK Global reportedly paid $25 million to cybercriminals after a mid-June ransomware attack disrupted business for thousands of car dealerships. According to a report from CNN citing multiple ...

As CDK Global continues making progress on bringing customers back onto its core platform after a crippling ransomware attack, cybersecurity experts told CRN that the massive disruption to car ...